Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia

The Pharmacogenomics Journal volume 11, pages 35–44 (2011)Cite this article

Subjects

Abstract

The objective of this study was to determine the association of 5-HT2C (serotonin 2C receptor) and MDR1 (multidrug resistant protein) genetic polymorphisms and antipsychotic-induced metabolic abnormalities among female patients with DSM IV schizophrenia spectrum disorders. We have previously reported the associations of −759CT 5-HT2C and G2677T and C3435T MDR1 genetic polymorphisms and olanzapine/risperidone-induced weight gain in a similar sample of patients. Here, we included a total of 101 previously non-medicated female patients treated with olanzapine/risperidone over a 3-month period. The variables analyzed included fasting glucose, total cholesterol, low-density lipoprotein, high-density lipoprotein and triglyceride levels in blood, blood pressure and waist circumferences. We observed significant association of −759T 5-HT2C genetic variant and greater increase in waist circumference (P=0.03), fasting glucose level (P=0.046) and triglyceride level (P=0.045) in blood after a 3-month period. The 2677T and 3435T MDR1 genetic variants were significantly associated with the greater increase in fasting glucose level in blood when patients were using olanzapine (P<0.001 and P=0.028, respectively). Our data indicate a possible influence of −759CT 5-HT2C and MDR1 G2677T and C3435T MDR1 genetic polymorphisms on the development of metabolic abnormalities among female patients treated with olanzapine/risperidone.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Stahl SM . Essential Psychopharmacology, Neuroscientific Basis and Practical Applications, 2nd edn. Cambridge University press: Cambridge, 2000.

    Google Scholar 

  2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.

    CAS  PubMed  Google Scholar 

  3. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A . Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenia patients. Int J Neuropsychopharmacol 2005; 8: 183–194.

    Article  CAS  PubMed  Google Scholar 

  4. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB et al. Effects of typical and atypical antipsychotics on glucose–insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006; 186: 572–578.

    Article  CAS  PubMed  Google Scholar 

  5. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf.

  6. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from III NHANES. Schizophr Res 2005; 80: 19–32.

    Article  PubMed  Google Scholar 

  7. Muller DJ, Kennedy JL . Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7: 863–887.

    Article  PubMed  Google Scholar 

  8. Rojnic Kuzman M, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H . The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 2008; 160: 308–315.

    Article  Google Scholar 

  9. Atmaca M, Kuloglu M, Tezcan E, Ustundag B . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598–604.

    Article  CAS  PubMed  Google Scholar 

  10. Thonnard-Neumann E . Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1946; 102: 108–110.

    Google Scholar 

  11. Di Matteo V, Cacchio M, Di Giulio C, Di Giovanni G, Esposito E . Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5-HT2C receptors in vivo. Pharmacol Biochem Behav 2002; 71: 607–613.

    Article  CAS  PubMed  Google Scholar 

  12. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF et al. Eating disorder and epilepsy in mice lacking 5HT2C serotonine receptors. Nature 1995; 374: 542–546.

    Article  CAS  PubMed  Google Scholar 

  13. Sugimoto Y, Inoue K, Yamada J . Involvement of 5-HT(2) receptor in imipramine-induced hyperglycemia in mice. Horm Metab Res 2003; 35: 511–516.

    Article  CAS  PubMed  Google Scholar 

  14. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL . 759C/T genetic variation of the 5HT2C receptor and clozapine-induced weight. Lancet 2002; 360: 1790–1791.

    Article  PubMed  Google Scholar 

  15. Tsai SJ, Hong CJ, Yu YW, Lin CH . 759C/T genetic variation of the 5HT2C receptor and clozapine-induced weight. Lancet 2002; 360: 1790.

    Article  PubMed  Google Scholar 

  16. Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Krieg JC et al. Lack of association between the −759C/T polymorphism of the 5HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004; 14: 139–142.

    Article  PubMed  Google Scholar 

  17. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F et al. Weight gain associated with the −759 C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005; 134B: 76–78.

    Article  PubMed  Google Scholar 

  18. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S . Clozapine-induced weight gain associated with the 5HT2C receptor −759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005; 133B: 97–100.

    Article  PubMed  Google Scholar 

  19. Templeman LA, Reynolds GP, Arranz B, San L . Polymorphisms of the 5HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15: 195–200.

    Article  CAS  PubMed  Google Scholar 

  20. Godlewska B, Olajossy-Hilkesberger L, Ciwoniuk M, Landowski J . 5-HT2C gene variant influences olanzapine-induced weight gain in men but not in women. Am J Med Genet B Neuropsychiatr Genet 2005; 141: 787: Abstract.

    Google Scholar 

  21. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL . Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007; 10: 697–704.

    Article  CAS  PubMed  Google Scholar 

  22. Yevtushenko O, Cooper S, O'Neill R, Doherty J, Reynolds G . 5-HT2C receptor and leptin polymorphism, obesity and metabolic syndrome in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 789: Abstract.

    Google Scholar 

  23. Mulder H, Franke B, Aart van der–Beek van der A, Arends J, Wilmink FW, Scheffer H et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27: 338–343.

    Article  CAS  PubMed  Google Scholar 

  24. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD . Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92–100.

    Article  CAS  PubMed  Google Scholar 

  25. Lin JH, Yamazaki M . Role of p-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42: 59–98.

    Article  CAS  PubMed  Google Scholar 

  26. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–698.

    Article  CAS  PubMed  Google Scholar 

  27. Boulton DW, DeVane CL, Liston HL, Markowitz JS . Human recombinant P-glycoprotein specificity for atypical antipsychotics. Life Sci 2002; 71: 163–169.

    Article  CAS  PubMed  Google Scholar 

  28. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002; 303: 1029–1037.

    Article  PubMed  Google Scholar 

  29. Uhr M, Grauer MT, Yassouridis A, Ebinger M . Blood–brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res 2007; 41: 179–188.

    Article  PubMed  Google Scholar 

  30. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlations of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–3478.

    Article  CAS  PubMed  Google Scholar 

  31. Lin YC, Ellingrod VL, Bishop JR, Miller del D . The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit 2006; 28: 668–672.

    Article  CAS  PubMed  Google Scholar 

  32. Medved V, Rojnic Kuzman M, Jovanovic N, Grubisin J, Kuzman T . Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. J Psychopharmacol 2008; 23: 915–922.

    Article  PubMed  Google Scholar 

  33. Miller SA, Dykes DD, Polesky HF . A simple salting out procedure for extracting DNA from human nucleated cell. Nucl Acid Res 1988; 16: 1215.

    Article  CAS  Google Scholar 

  34. Guo SW, Thompson EA . Performing the exact test of Hardy–Weinberg proportions for multiple alleles. Biometrics 1992; 48: 361–372.

    Article  CAS  PubMed  Google Scholar 

  35. Slatkin M, Excoffier L . Testing for linkage disequilibrium in genotypic data using the EM algorithm. Heredity 1996; 76: 377–383.

    Article  PubMed  Google Scholar 

  36. Excoffier L, Laval G, Schneider S . Arlequin ver. 3.01: An Integrated Software Package for Population Genetic Data Analysis. University of Bern: Switzerland, 2006.

    Google Scholar 

  37. Dudbridge F . Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115–121.

    Article  PubMed  Google Scholar 

  38. Holm S . A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65–70.

    Google Scholar 

  39. Rice WR . Analyzing tables of statistical tests. Evolution 1989; 43: 223–225.

    Article  Google Scholar 

  40. Lin PI, Vance JM, Pericak-Vance MA, Martin ER . No gene is an Island: The flip-flop phenomenon. Am J Hum Genet 2007; 80: 531–538.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. McCarthy S, Mottagui-Tabarn S, Mizuno Y, Sennblad B, Hoffstedt J, Arner P et al. Complex HRT2C linkage disequilibrium and promoter associations with body mass index and serum leptin. Hum Genet 2005; 117: 545–557.

    Article  CAS  PubMed  Google Scholar 

  42. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K . Identification of polymorphic loci in the promoter region of the serotonin 5HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43: 37s.

    Article  Google Scholar 

  43. Buckland PR, Hoogendoorn B, Guy CA, Smith SK, Coleman SL, O'Donovan MC . Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry 2005; 162: 613–615.

    Article  PubMed  Google Scholar 

  44. Gundlah C, Pecins-Thompson M, Schutzer WE, Bethea CL . Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res Mol Brain Res 1999; 63: 325–339.

    Article  CAS  PubMed  Google Scholar 

  45. Buckland PR, D'Souza U, Maher NA, McGuffin P . The effects of antipsychotic drugs on the mRNA levels of serotonin 5-HT and 5-HT receptors. Brain Res Mol Brain Res 1997; 48: 45–52.

    Article  CAS  PubMed  Google Scholar 

  46. Burnet PWJ, Chen CPL-H, McGowan S, Franklin M, Harrison PJ . The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 1996; 73: 531–540.

    Article  CAS  PubMed  Google Scholar 

  47. Canton H, Emeson RB, Barker EL, Backstrom JR, Lu JT, Chang MS et al. Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine 2C receptor produced by alternative splicing. Mol Pharmacol 1996; 59: 799–807.

    Google Scholar 

  48. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19–28.

    Article  CAS  PubMed  Google Scholar 

  49. Moffat AC, Osselton MD, Widdop B . Clark's analysis of drugs and poisons, vol. 2. Pharmaceutical Press: London, 2004.

    Google Scholar 

  50. Ader M . Looking beyond the weight gain: preclinical evidence of antipsychotic—induced adiposity and pancreatic dysfunction. World J Biol Psychiatry 2007; 8 (Suppl 1): 47.

    Google Scholar 

  51. Koller EA, Cross JT, Doraiswamy PM, Malozowski SN . Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003; 23: 1123–1130.

    Article  CAS  PubMed  Google Scholar 

  52. Rossor AM, Leech N, Neely RDG . Olanzapine-induced chylomicronemia presenting as acute pancreatitis. J Clin Psychopharmacol 2007; 27: 395–396.

    Article  PubMed  Google Scholar 

  53. Aichhorn W, Gasser M, Weiss EM, Adlassnig C, Marksteiner J . Gender differences in pharmacokinetics and side effects of second generation antipsychotic drugs. Curr Neuropharmacol 2005; 3: 73–85.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank our colleagues D Vukelja and M Mahnik for their help in data collection and Ministry of Science, Education and Sport for sponsoring this study.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University Hospital Centre Zagreb and Zagreb School of Medicine, Zagreb, Croatia

    M R Kuzman, V Medved, J Grubišin & N Jovanovic

  2. Clinic for Laboratory Diagnosis, University Hospital Centre Zagreb, Zagreb, Croatia,

    N Bozina & J Sertic

Authors
  1. M R Kuzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Medved
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Bozina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Grubišin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Jovanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Sertic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M R Kuzman.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kuzman, M., Medved, V., Bozina, N. et al. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J 11, 35–44 (2011). https://doi.org/10.1038/tpj.2010.7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.7

Keywords

  • schizophrenia
  • metabolic syndrome
  • glucose
  • 5HT2C
  • MDR1
  • antipsychotics

This article is cited by

Search

Advanced search

Quick links